OncoMatch/Clinical Trials/NCT07153887
Vebreltinib for Advanced or Metastatic CCS
Is NCT07153887 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Vebreltinib for clear cell sarcoma (ccs).
Treatment: Vebreltinib — This is a prospective, cohort, multicenter study. Cohort 1 is treatment group. All eligible subjects will receive Vebreltinib (200 mg bid po) after signing the informed consent and meeting the inclusion/exclusion criteria, until disease progression, intolerable toxicity, or death. Subjects will undergo MET abnormality testing after enrollment, including MET amplification or MET protein overexpression. Cohort 2 is external reference group. Subjects diagnosed with CCS and met the inclusion criteria but refused to enter Cohort1 will receive the standard treatment decided by investigators. These subjects will receive follow-up. The efficacy and safety data will be collected. Imaging evaluation will be performed using RECIST v1.1, with CT or MR plain scans every two months (±7 days) until disease recurrence or death. During the study, subjects will receive safety follow-up, and survival follow-up will be conducted every two months after treatment, which can be done by telephone interview for approximately 3 years after treatment ends.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Sarcoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: class Ib MET inhibitor
Previous treatment with class Ib MET inhibitors
Cannot have received: MET inhibitor (cabozantinib)
Previous treatment with ... cabozantinib
Lab requirements
Blood counts
Hemoglobin (HB) ≥90g/L; Absolute neutrophil count (ANC) ≥1.5×10⁹/L; Platelets (PLT) ≥100×10⁹/L
Kidney function
Serum creatinine ≤1.5×ULN or creatinine clearance (CCr) ≥60ml/min; Urine protein <2+, and 24h urine protein quantitation ≤1g
Liver function
Total bilirubin ≤1.5× ULN; ALT and AST ≤2.5×ULN, and if with liver metastasis, ALT and AST ≤5×ULN
Cardiac function
Left ventricular ejection fraction (LVEF) ≥ lower limit of normal (60%)
Normal function of major organs, meeting the following criteria within 7 days before treatment:① Hematology examination criteria must be met (without blood transfusion or blood products, and without correction by G-CSF or other hematopoietic stimulating factors within 14 days):a) Hemoglobin (HB) ≥90g/L; b) Absolute neutrophil count (ANC) ≥1.5×10⁹/L; c) Platelets (PLT) ≥100×10⁹/L; ② Biochemical examination must meet the following criteria: a) Total bilirubin (TBIL) ≤1.5× upper limit of normal (ULN); b) Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×ULN, and if with liver metastasis，ALT and AST ≤5×ULN; c) Serum creatinine (Cr) ≤1.5×ULN or creatinine clearance (CCr) ≥60ml/min; ③ Urine protein <2+, and 24h urine protein quantitation shows protein ≤1g; ④ Coagulation function: INR <2.0 and APTT ≤1.5×ULN ⑤ Doppler ultrasound assessment: Left ventricular ejection fraction (LVEF) ≥ lower limit of normal (60%) ⑥ Thyroid function: TSH ≤ upper limit of normal (ULN); if abnormal, T3 and T4 levels should be considered, and subjects can be enrolled if T3 and T4 levels are normal;
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07153887 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior class Ib MET inhibitor, MET inhibitor disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages